Does low-dose heparin maintain central venous access device patency? A comparison of heparin versus saline during a period of heparin shortage

Journal of Parenteral and Enteral Nutrition

Volumn 34, Issue 4, 2010, Pages 444-449

  Jonker, Mark A ^b   Osterby, Kurt R ^c   Vermeulen, Lee C ^c   Kleppin, Susan M ^d   Kudsk, Kenneth A ^a,b  

^a WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d Waukesha Memorial Hospital   (United States)

Author keywords

adults; alteplase; central venous access; heparin flush; thrombosis

Indexed keywords

ALTEPLASE; HEPARIN; SODIUM CHLORIDE;

ARTICLE; CENTRAL VENOUS CATHETER; CENTRAL VENOUS CATHETERIZATION; COHORT ANALYSIS; DATA BASE; DEVICE REMOVAL; DRUG COST; DRUG EFFICACY; HUMAN; LOW DRUG DOSE; OCCLUSION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOSIS;

ADULT; CATHETERIZATION, CENTRAL VENOUS; CATHETERS, INDWELLING; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; LENGTH OF STAY; RETROSPECTIVE STUDIES; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; VASCULAR PATENCY;

EID: 77956249142     PISSN: 01486071     EISSN: None     Source Type: Journal    
DOI: 10.1177/0148607110362082     Document Type: Article

References (27)

1. Kerner JA Jr, Garcia-Careaga MG, Fisher AA, Poole RL Treatment of catheter occlusion in pediatric patients. JPEN J Parenter Enteral Nutr. 2006 ; 30 (1 suppl). S73 - S81.
2. Lokich J., Bothe A. Jr, Benotti P., Moore C. Complications and management of implanted venous access catheters. J Clin Oncol. 1985 ; 3: 710-717.
3. Baumgartner J., Cooper S.,. Influence of thrombus components in mediating Staphylococcus aureus adhesion to polyurethane surfaces. J Biomed Mater Res. 1998 ; 40: 660-670.
4. Barzaghi A., Dell'Orto M., Rovelli A., Rizzari C., Colombini A., Uderzo C. Central venous catheter clots: incidence, clinical significance and catheter care in patients with hematologic malignancies. Pediatr Hematol Oncol. 1995 ; 12: 243-250.
5. Kuter DJ Thrombotic complications of central venous catheters in cancer patients. Oncologist. 2004 ; 9: 207-216.
6. Ponec D., Irwin D., Haire WD, et al. Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial- the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial. J Vasc Interv Radiol. 2001 ; 12: 951-955.
7. Deitcher SR, Fesen MR, Kiproff PM, et al. Safety and efficacy of alteplase for restoring function in occluded central venous catheters: results of the cardiovascular thrombolytic to open occluded lines trial. J Clin Oncol. 2002 ; 20: 317-324.
8. Stephens LC, Haire WD, Tarantolo S., et al. Normal saline versus heparin flush for maintaining central venous catheter patency during apheresis collection of peripheral blood stem cells (PBSC). Transfus Sci. 1997 ; 18: 187-193.
9. Smith S., Dawson S., Hennessey R., Andrew M. Maintenance of the patency of indwelling central venous catheters: is heparin necessary ? Am J Pediatr Hematol Oncol. 1991 ; 13: 141-143.
10. LeDuc K. Efficacy of normal saline solution versus heparin solution for maintaining patency of peripheral intravenous catheters in children. J Emerg Nurs. 1997 ; 23: 306-309.
11. Goode CJ, Kleiber C., Titler M., et al. Improving practice through research: the case of heparin vs. saline for peripheral intermittent infusion devices. Medsurg Nurs. 1993 ; 2: 23-27.
12. Geritz M. Saline versus heparin in intermittent infuser patency maintenance. West J Nurs Res. 1992 ; 14: 131-137.
13. Hamilton RA, Plis JM, Clay C., Sylvan L. Heparin sodium versus 0.9% sodium chloride injection for maintaining patency of indwelling intermittent infusion devices. Clin Pharm. 1988 ; 7: 439-443.
14. Tuten S., Gueldner S. Efficacy of sodium chloride versus dilute heparin for maintenance of peripheral intermittent intravenous devices. Appl Nurs Res. 1991 ; 4: 63-71.
15. Randolph AG, Cook DJ, Gonzales CA, Andrew M. Benefit of heparin in peripheral venous and arterial catheters: systematic review and meta-analysis of randomised controlled trials. BMJ. 1998 ; 316: 969-975.
16. Heeger PS, Backstrom JT Heparin flushes and thrombocytopenia. Ann Intern Med. 1986 ; 105: 143.
17. Warkentin TE, Levine MN, Hirsh J., et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995 ; 332: 1330-1335.
18. Passannante A., Macik B. The heparin flush syndrome: a cause of iatrogenic hemorrhage. Am J Med Sci. 1988 ; 296: 71-73.
19. Doty JR, Alving BM, McDonnell DE, Ondra SL Heparin-associated thrombocytopenia in the neurosurgical patient. Neurosurgery. 1986 ; 19: 69-72.
20. Goode CJ, Titler M., Rakel B., et al. A meta-analysis of effects of heparin flush and saline flush: quality and cost implications. Nurs Res. 1991 ; 40: 324-330.
21. Blossom DB, Kallen AJ, Patel PR, et al. Outbreak of adverse reactions associated with contaminated heparin. N Engl J Med. 2008 ; 359: 2674-2684.
22. Davis SN, Vermeulen L., Banton J., Schwartz BS, Williams EC Activity and dosage of alteplase dilution for clearing occlusions of venous-access devices. Am J Health Syst Pharm. 2000 ; 57: 1039-1045.
23. Anderson AJ, Krasnow SH, Boyer MW, et al. Hickman catheter clots: a common occurrence despite daily heparin flushing. Cancer Treat Rep. 1987 ; 71: 651-653.
24. Rabe C., Gramann T., Sons X., et al. Keeping central venous lines open: a prospective comparison of heparin, vitamin C and sodium chloride sealing solutions in medical patients. Intensive Care Med. 2002 ; 28: 1172-1176.
25. Andersen K., Holland J. Maintaining the patency of peripherally inserted central catheters with 10 units/cc heparin. J Intraven Nurs. 1992 ; 15: 84-88.
26. Baumer AM, Clark AM, Witmer DR, Geize SB, Vermeulen LC, Deffenbaugh JH National survey of the impact of drug shortages in acute care hospitals. Am J Health Syst Pharm. 2004 ; 61: 2015-2022.
27. Fox E., Tyler L. Managing drug shortages: seven years' experience at one health system. Am J Health Syst Pharm. 2003 ; 60: 245-253.